Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,528.60INR
10:14am GMT
Change (% chg)

Rs51.55 (+2.08%)
Prev Close
Rs2,477.05
Open
Rs2,545.50
Day's High
Rs2,545.60
Day's Low
Rs2,490.00
Volume
947,022
Avg. Vol
926,983
52-wk High
Rs2,670.80
52-wk Low
Rs1,887.00

Select another date:

Thu, Nov 1 2018

UPDATE 2-Cost cuts help drugmaker Indivior as it battles cheap rival

* Shares give back early gains to trade lower (Adds details on the company's drugs, background, comments)

UPDATE 1-Indian drugmaker Dr. Reddy's Q2 profit soars past market estimates

Oct 26 Dr.Reddy's Laboratories posted a better-than-expected rise in second-quarter profit as higher sales in some emerging countries offset a marginal decline in business in North America, a key market for the Indian generic drugmaker.

India's Dr.Reddy's profit soars on anti-opioid drug sales in U.S.

Indian generic drugmaker Dr.Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the U.S. launch of a generic version of an opioid addiction drug.

UPDATE 1-India's Dr.Reddy's profit soars on anti-opioid drug sales in U.S.

July 26 Indian generic drugmaker Dr.Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the U.S. launch of a generic version of an opioid addiction drug.

India's Dr. Reddy's Q1 net profit rises seven-fold, beats forecast

July 26 Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the launch of a generic version of an opioid addiction drug.

UPDATE 3-British drugmaker Indivior's shares hit by copycat, new drug worries

* New drug Sublocade's initial H1 sales below Jefferies estimate

RPT-UPDATE 2-Indivior shares plummet on warning of bigger hit from copycat drug

* New drug Sublocade's initial H1 sales below Jefferies estimate

Indivior warning on anti-opioid drug competition sends shares tumbling

British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

Select another date: